Muscarinic agonist

From Wikipedia, the free encyclopedia

A muscarinic receptor agonist is an agent that enhances the activity of the muscarinic acetylcholine receptor. The muscarinic receptor has different subtypes, labelled M1-M5, allowing for further differentiation.

1 Clinical significance

1.1 M1 1.2 M3

[edit] Clinical significance

[edit] M1

M1-type muscarinic acetylcholine receptors play a role in cognitive processing. In Alzheimer disease (AD) amyloid formation may decrease the ability of these receptors to transmit their signals leading to decrease cholinergic activity. As these receptors themselves appear relatively unchanged in the disease process, they have become a potential therapeutic target when trying to improve cognitive function in patients with AD.^[1]^[2]^[3]

A number of muscarinic agonists have been developed and are under investigation to treat AD. These agents show promise as they are neurotrophic, decrease amyloid depositions, and improve damage due to oxidative stress. Tau-phosphorylation is decreased and cholinergic function enhanced. Notably several agents of the AF series of muscarinic agonists have become the focus of such research:. AF102B, AF150(S), AF267B. In animal models that are mimicking the damage of AD, these agents appear promising.

The agent xanomeline has been proposed as a potential treatment for schizophrenia.^[4]

[edit] M3

In the form of pilocarpine muscarinic receptor agonists have been used medically for a long time.

M3 agonists

Aceclidine, for glaucoma. Arecoline, an alkaloid present in the Betel nut. Pilocarpine is a drug that acts as a muscarinic receptor agonist that is used to treat glaucoma. Cevimeline (AF102B) (EvoxacÂ™) is a muscarinic agonist that is an Food and Drug Administration (FDA)-approved drug and used for the management of dry mouth in SjÃ¶gren's syndrome.

[edit] See also

Muscarine

[edit] References

^ Fisher A, Brandeis R, Bar-Ner RH, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):145-53. PMID 12212772 ^ Fisher A. M1 muscarinic agonists: Their potential in treatment and as disease-modifying agents in Alzheimer's disease Drug Dev. Res. 50:291-297, 2000. [1] ^ Fisher A (July 2008). "Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease". Neurotherapeutics 5 (3): 433â€“42. doi:10.1016/j.nurt.2008.05.002. PMID 18625455. ^ Shekhar A, Potter WZ, Lightfoot J, et al (July 2008). "Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia". Am J Psychiatry. doi:10.1176/appi.ajp.2008.06091591. PMID 18593778.